SpainSpain

Capital Increase Take-off for Natraceutical: Euro20 Million

08.05.2004

Madrid - The Board of Spanish specialist for food, Natraceutical, approved in its April meeting the issue of 38,521,165 new shares, for a nominal amount of Euro3,852,116.5, allowing it to raise Euro20,031,005.80. The new shares will have the same rights as all bonds currently in circulation, taking effect from January 1, 2004, and with an issue price of Euro0.52.
Upon the approval of the prospectus by the Comisión Nacional de Mercado de Valores CNMV (National Stock Exchange Comission) , a 10-day period will be established to enable Natraceutical's shareholders to subscribe 5 new shares for every 19 old shares in their possession the day before this preferential subscription period commences and in which the rights, valued according to closing on April 22 at Euro0.075, will also be listed.
The Euro20 million , which Natraceutical will raise, will enable it to strengthen its resources and deal with projects which are included in the prospectus of its floating on the stock market, in addition to other product or business lines in which it's working.
Natraceutical currently markets 22 functional ingredients for the food industry. During 2003 and 2004 it has applied for five patents for functional ingredients and active principles, all derived from raw, natural materials, especially from the Mediterranean area. The company produces active compunds and biotechnological ingredients and develops functional foods as well. It also takes part in Biópolis, a biotechnological company directed at custom-made R&D activities for the food and pharmaceutical sectors, which was launched in April 2003 with the Consejo Superior de Investigaciones Científicas (Board of Scientific Research-CSIC), CAPSA and the Capital-Risk entity, TALDE. In 2003, Natraceutical achieved net profits of Euro2 million, thus multiplying six-fold its previous year's profits.
The world market for functional ingredients and nutraceuticals, whose main markets are the United States and Japan, rose to more than $34 billion in 2002, reflecting a growth of 9.2% compared with the previous year.

SpainSpain

08.03.2012

Granada-based Integromics S.L. has teamed up with the Galician Foundation of Genomic Medicine (FPGMX) in Santiago de Compostela to secure a €1m EU grant from the European Regional Development Fund and the Spanish government. With...

SpainSpain

08.03.2012

Oryzon Genomics S.A (Barcelona) is entering preclinical testing with a first-in-class bispecific LSD1/MAO-B inhibitor. In addition to the classic target MAO-B, the drug also blocks histone demethylase LSD1, an epigenetic histone...

SpainSpain

06.03.2012

Granada-based nLife Therapeutics S.L. has raised €5m in total from two venture capitalists. Through Caixa Capital Risc and Caixa Capital Biomed, La Caixa invested €2.5m. The same amount has been placed by Invercaria via its...

SpainSpain

05.03.2012

Ordesa Laboratories has filed a patent for a novel Bifidobacterium strain isolated from infant feces. It has the capacity to combat rotavirus, says a study (Appl. Environ. Microbiol., doi:10.1128/AEM.05548).

SpainSpain

19.12.2011

Madrid – Researchers from Spain and the US have discovered an Ebola-like filovirus in bats in northern Spain. The first known filovirus native to Europe was reported in a study published in the journal PLOS Pathogens...

SpainSpain

15.12.2011

Barcelona - South western Europe gets a new R&D unit in the field of biomolecules. Kymos Pharma, a contract researcher based in Barcelona, has signed an agreement with the French biotechnology group Ipsen to create a R&D group...

SpainSpain

12.12.2011

Barcelona/Saffron Walden – Almirall S.A. and BioFocus announced that they have entered into a collaboration agreement to identify new compounds against key targets in projects aimed at the treatment of respiratory and...

SpainSpain

03.12.2011

Madrid/Abu Dhabi – Spanish biotechs are seeking collaborations with firms in the United Arab Emirates. At the end of November, Grupo Zeltia and 14 other Spanish companies presented their research at the forum “Innovation,...

SpainSpain

01.10.2011

Madrid – The Spanish Minister of Innovation and Science Cristina Garmendia has responded to reports about Roche’s­ delivery stop in Greece and pessimistic expectations for Spain. In Sept­ember, she stressed that the atmosphere...

Displaying results 1 to 10 out of 181

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/messages-archive/archive-spain/article/capital-increase-take-off-for-natraceutical-euro20-million.html

Print Magazine

Product of the week

Products

Events

All Events

Partner-Events

Stock list

All quotes

TOP

  • 4SC0.94 EUR2.17%
  • ACTELION108.70 CHF0.00%
  • ADDEX3.07 CHF0.00%

FLOP

  • CYTOTOOLS31.45 EUR-0.47%
  • ACTELION108.70 CHF0.00%
  • ADDEX3.07 CHF0.00%

TOP

  • CYTOS0.28 CHF64.7%
  • EPIGENOMICS5.15 EUR47.1%
  • STRATEC BIOMEDICAL48.50 EUR26.5%

FLOP

  • BIOFRONTERA2.52 EUR-13.7%
  • CO.DON2.51 EUR-11.6%
  • ADDEX3.07 CHF-9.7%

TOP

  • SANTHERA91.30 CHF2585.3%
  • CO.DON2.51 EUR139.0%
  • BB BIOTECH181.25 EUR63.4%

FLOP

  • CYTOS0.28 CHF-91.8%
  • 4SC0.94 EUR-46.0%
  • MOLOGEN7.35 EUR-41.4%

No liability assumed, Date: 21.11.2014

Current issue

All issues